Format

Send to

Choose Destination
Ann Transl Med. 2016 Dec;4(24):543. doi: 10.21037/atm.2016.11.77.

What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.

Author information

1
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center